Measles confirmed in Newman miner and Qantas staff member
It's understood the initial case developed in a miner who had been working at the BHP mine site in Newman, an outback WA mining town, in early July.
BHP confirmed it was monitoring another staff member, still at the site, who had developed a confirmed case of measles and several others who were isolating as a precaution because they were presenting symptoms.
'Our health and safety team has implemented precautionary measures for the wellbeing of our workforce and the community,' a BHP spokesman told Perth Now.
It's understood the person harbouring the initial case of measles had flown on Qantas Flight QF1705 from Newman to Perth on June 23 before making their way back to Newman on flight QF1708 on July 2.
A Qantas spokesman confirmed to Perth Now that one of the flight crew contracted measles after a flight in early July.
'We advised WA health of our team member's positive diagnosis and conducted contact tracing internally to identify other staff who may have been in contact with the impacted crew member,' he said.
The crew member is isolating, and no further symptoms are present.
The WA Department of Health has advised anybody who 'visited an exposure location ' during the indicated dates and times to pay attention to any possible symptom developments for 'between 7 to 18 days'.
'Persons who have received two measles vaccinations and those born before 1966 are considered immune to measles. On rare occasions, vaccinated individuals may develop a mild illness,' the department said.
'Anyone who has travelled overseas or attended any of the above listed areas, and are not immune to measles, are at risk of developing measles. Those presenting signs and symptoms of measles should be tested.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
3 hours ago
- News.com.au
MoneyTalks: Summit Biotech Fund's three standout ASX healthcare stocks
MoneyTalks is Stockhead's drill down into what stocks investors are looking at right now. We tap our list of experts to hear what's hot, their top picks and what they're looking out for. Today we hear from Australia's Summit Biotech Fund manager Reece O'Connell. With experience trading through multiple economic and market cycles, Reece O'Connell has developed a long-term investment approach focused on preserving and growing capital. In a career that has taken him from Perth to London and back again, he has worked closely with high-net-worth and wholesale investors, tailoring strategies to meet their objectives while navigating changing market conditions. At Summit Biotech Fund (SBF) he aims to provide long-term capital growth by investing in a portfolio of life science companies where innovation plays a crucial role in improving global health and economic outcomes. This includes biotechnology, pharmaceuticals, medical devices and equipment, medical data, information technology (e-health), and robotics. And in some good news for the fund, a rotation back into the healthcare sector appears to be gaining momentum with the S&P ASX 200 Health Care index rising 9.05% in July. "The healthcare sector has been the worst performing sector for two years and there's great positioning in quality healthcare names before the sector turns," he said. "We see these sector rotations every three to five years and I believe the ASX healthcare sector represents good value and plenty of upside in quality names with strong management." Here's three companies Summit Biotech Fund has invested in and why. Arovella Therapeutics (ASX:ALA) SBF is a major shareholder in Arovella, which is developing a next-generation cell therapy platform based on invariant Natural Killer T (iNKT) cells engineered with Chimeric Antigen Receptors (CARs) to target specific cancer antigens. Unlike traditional CAR-T therapies, Arovella's approach uses healthy donor cells to create off-the-shelf treatments, which reduces cost, complexity and time to treatment — the major issues currently faced by CAR-T companies. Arovella's lead candidate, ALA-101, targets CD19-positive blood cancers, and its pipeline encompasses therapy development for solid tumours such as gastric and pancreatic cancers. O'Connell reckons Arovella is in a hot area of cancer research. Nasdaq-listed MiNK Therapeutics recently soared following publication of a case report in the peer-reviewed Oncogene journal, detailing a patient with advanced, treatment-refractory testicular cancer who achieved complete remission after receiving its lead product iNKT Agentâ€'797, in combination with the immune checkpoint inhibitor nivolumab. "Arovella presents an opportunity in a rapidly growing sector, with a differentiated platform and strong early-stage clinical momentum," O'Connell said. "The company is the only ASX-listed biotech delving into CAR-iNKT therapies and one of only a handful globally." He said Arovella was well funded, finishing Q4 FY25 with cash of $20.9 million, which should fund the company through to completion of patient enrolment for its phase I clinical trial for ALA-101 n non-Hodgkin's lymphoma and leukaemia patients exhibiting the CD-19 biomarker – the target its CAR-iNKT cells recognise. The funding will also support the advancement of the company's solid tumour programs (CLDN18.2-CAR-iNKT targeting gastric cancer) and its armouring program (IL-12-TM). "ALA presents a highly compelling investment opportunity over the next six to 12 months, given the competitive landscape and the deals being struck for allogeneic assets and platforms," O'Connell added. SBF is a significant shareholder in Tryptamine, a clinical-stage biopharmaceutical company developing next-generation psychedelic medicines for neuropsychiatric conditions. Its lead program, TRP-8803, is a proprietary, IV-delivered formulation of psilocybin designed to provide more precise dosing and improved patient tolerability compared to oral psychedelic treatments. Phase 1b trials have already shown the drug to be safe and well tolerated in obese and non-obese participants. The company recently kicked off a world-first psilocin trial with TRP-8803 targeting Binge Eating Disorder (BED). The study, run in collaboration with Swinburne, will assess TRP-8803 when administered with psychotherapy with the goal to evaluate safety, feasibility and efficacy in adults diagnosed with BED. For O'Connell when analysing a biotech it as much about who is running the company as it is about the science. "One of the most important investment themes I always look for is a material monetary investment by directors in a company," he said. "Too many small ASX-listed companies have boards that aren't truly aligned with shareholders. "The number one way to be aligned is to have directors putting in their hard-earned cash like us. In this case, TYP ticks all the boxes.' He said directors, management,and major shareholders were collectively invested for more than $9m, with CEO Jason Carroll personally contributing more than $1 million. Carroll's 30-year career in big pharma includes two decades at Johnson & Johnson, where he led the strategy that doubled US sales of Remicade — a blockbuster IBD drug that ultimately reached US$10bn in annual global sales. O'Connell said other board members brought similar firepower. Executive director Chris Ntoumenopoulos was involved in the growth of Race Oncology (ASX:RAC) from $10m to north of $200m, founded former ASX-listed ResApp Health, which was acquired by Pfizer for ~$200m, and has helped double Island Pharmaceuticals' (ASX:ILA) value since joining its board. As part of the last raise experienced biotech investor Dr Daniel Tillett joined the Tryptamine board as a non-executive director and became a cornerstone investor. Tillet also cornerstoned a raise in Race Oncology in its early days and now leads it as CEO and managing director. Recent clinical progress provides Tryptamine with valuable proprietary data as its seek to advance the use of TRP-8803 in patient-specific indications. "With a differentiated psychedelic platform, directors heavily invested alongside shareholders, and multiple catalysts on the horizon, Tryptamine is emerging as one of the more compelling plays in the sector," O'Connell said. SBF also holds a strong position in NeuroScientific, which O'Connell said was positioning itself as a serious player in the fast-growing field of stem cell therapies for immune-mediated diseases, underpinned by its recently acquired StemSmart platform. The patented mesenchymal stromal cell (MSC) therapy has shown strong early results including a 53% remission rate in a phase II trial for refractory Crohn's disease and outperforming Humira, the long-time anti-inflammatory drug used as a standard of care. It also showed high response rates in a phase I trial for steroid-refractory Graft-versus-Host Disease (GvHD). "With the global markets for Crohn's and GvHD forecast to reach US$25 billion combined by 2035, StemSmart is tapping into significant unmet needs," O'Connell said. He also sees validation from the sector's leader Mesoblast (ASX:MSB), which recently secured US Food and Drug Administration (FDA) approval for its MSC product and now commands a $3.1bn market cap. He said by comparison, Neuroscientific trades at just ~23 cents but carries a midpoint valuation of 60 cents, representing around 161% upside based on a probability-adjusted DCF model assuming modest success rates and future partnerships. This assumes modest 20% success rates, 25% market penetration in Crohn's and potential partnerships with big pharma to fund late-stage trials. With a Special Access Program about to generate real-world data, plans to initiate Phase II trials in 18–24 months, and expansion into additional inflammatory and lung diseases, StemSmart offers a scalable pipeline. "For investors looking at the MSC space NSB could be an early-stage, high-upside opportunity positioned to follow Mesoblast's trajectory as the market matures," he said. The views, information, or opinions expressed in the interview in this article are solely those of the interviewee and do not represent the views of Stockhead. Stockhead has not provided, endorsed or otherwise assumed responsibility for any financial product advice contained in this article. Disclosure: Summit Biotech Fund held shares in Arovella, Tryptamine Therapeutics and NeuroScientific Biopharmaceuticals at the time of writing this article.
ABC News
a day ago
- ABC News
As Samoa battles dengue fever, here's what you need to know about the mosquito-borne virus
Each morning in Samoa, fumigation teams gear up to spray schools and buildings, battling tirelessly against a dengue outbreak. Since the outbreak was declared on April 17, Samoa's Ministry of Health says more than 5,600 clinically diagnosed cases have been recorded. Tragically, to date, there have been four confirmed and one probable dengue-related death, highlighting the urgent fight still ahead. This effort comes as the Pacific faces a severe surge in cases, with deaths now reported in Fiji, Tonga, and Nauru. Affected countries also include American Samoa, Cook Islands, Tahiti, Kiribati and Tuvalu. So what is dengue fever? And why is this outbreak hitting the Pacific so hard? Samoa has rolled out a large-scale fumigation program in schools. ( Image: Ministry of Health Samoa ) What is causing the current dengue outbreak? Dengue fever is a viral disease spread by mosquitoes. It is transmitted by the infected female Aedes mosquito and causes fever and joint pain. Some patients can suffer internal bleeding, which can cause death. It has long plagued tropical nations, but health experts warn the 2025 outbreak is one of the worst in almost a decade. This is largely because of: In Fiji, the WHO's July data shows the spread of the disease has been highest. ( Source: Fiji's Ministry of Health & Medical Services ) What are the symptoms? Symptoms to watch for include fever, extreme fatigue, headache, nausea, vomiting, intense muscle and joint pains, and a distinct measles-like rash. Dengue cases in the Pacific are at their highest since 2016, with nearly 19,000 people affected as of last month's figures, the World Health Organisation (WHO) says. Aedes aegypti is the primary spreader of dengue. Dengue is the most common mosquito-borne disease worldwide. ( Supplied: Stephen Doggett, NSW Health Pathology ) Globally, the WHO recorded more than 13 million dengue cases and 9,990 deaths in 2024. Aedes aegypti mosquitoes are the primary spreaders of dengue, although another species — Aedes albopictus (commonly known as the Asian tiger mosquito) — can also carry the virus. How can it be stopped? Prevention measures include: Eliminating stagnant/ standing water sources — like tyres, open buckets, water-holding containers, etc Eliminating stagnant/ standing water sources — like tyres, open buckets, water-holding containers, etc Use mosquito nets and repellent Use mosquito nets and repellent Wearing long-sleeved clothing Wearing long-sleeved clothing Keep the surrounding areas clean Keep the surrounding areas clean Community spray In recent weeks, Samoa has been particularly affected. Just in the past seven days, more than 1,400 new clinically diagnosed cases have been reported across Upolu and Savai'i. There, families and villages have been urged to actively eliminate mosquito breeding sites by improving waste disposal, removing stagnant water, and clearing overgrown vegetation to reduce mosquito populations. Adapting scientific solutions to the Pacific A mosquito release program in Far North Queensland using Wolbachia bacteria helped reduce dengue transmission by making mosquitoes more resistant to the virus and less likely to infect humans. Mosquitoes bred in jars as part of the World Mosquito Program's dengue fever eradication program. ( Supplied: World Mosquito Program ) Dr Tessa Knox, co-lead of the Pacific Mosquito Strengthening for Impact (PacMOSSI) consortium. ( Supplied. ) Although the method proved highly effective in Australia, applying similar scientific interventions in the Pacific presents unique challenges, Tessa Knox from PacMOSSI explains. "Not all mosquito control interventions are suitable for every setting. The Pacific Islands face numerous challenges: a diversity of mosquito species, remote and dispersed populations, limited human resources, fragile health systems, and competing health priorities. "These factors create significant logistical, technical, and resource barriers. Locally tailored solutions are therefore essential. "Across the Pacific, there is great diversity in the species that can transmit dengue. It is important to know which species are found in which habitats and understand when and where they bite people and transmit dengue." Fighting dengue with better mosquito control and insecticide use PacMOSSI is working to support Pacific Island Ministries of Health to improve this knowledge to tailor control strategies against local dengue mosquitoes. The consortium connects 21 Pacific Island countries with seven international institutions to combat mosquito-borne diseases. "Community-led approaches like removing rubbish in yards and public areas to reduce mosquito water habitats are essential. Knowing which species can be killed with which insecticides helps to select the best option for spray teams to use when responding to a dengue outbreak," Dr Knox told ABC Pacific.
ABC News
3 days ago
- ABC News
Why WA may have to shift its focus to making ambulance ramping safer
Across Western Australia, ambulances spent more than 7,000 hours parked outside the state's hospitals last month. That figure breaks all previous records — even those set during the height of COVID. It goes without saying, that's a big problem. Those ambulance crews aren't on the road answering other calls, and patients are receiving less-than-ideal care. In the grand scheme of the behemoth that is Western Australia's health system, it is also a symptom of much deeper problems, according to experts. The first problem is the state does not have enough hospital beds to meet demand. On the most recent data (up to mid-2023) Western Australia had the second-lowest rate of hospital beds based on population out of all states and territories. For comparison, if WA had the same ratio of beds per person as the highest state – Tasmania – it would have had an extra 1,500 or so places. 'We've delivered over 900 beds to the hospital system since 2021, we've increased staff by 30 per cent and we're looking at innovative ways that we can deliver care,' Health Minister Meredith Hammat said on Friday. But the state still needed 'at least 1,000 more beds', according to the Australian Medical Association. 'At the end of the day, we need more beds. We need more capacity in our health system. It really can't get any simpler than that,' WA President Kyle Hoath said. Those beds can take a long time to build and bring online – not the solution you want in the middle of an immediate crisis. There's also the problem, the government says, of too many beds being taken up by people who could be in aged care. But solving the problems in that sector is not quick or straightforward, either. Dr Hoath's solution was to look to private hospitals and medi-hotels, where he said there was spare capacity. 'There are beds there that could be used as hospital beds and we need to take advantage of that,' he said. Ms Hammat wasn't giving away whether she thought that was a good idea though. It was a similar answer she gave to almost every question – repeating that phrase 17 times in about 14 minutes while offering no new ideas on how to tackle the problem. The second problem ramping reveals, according to Dr Hoath, is that the hospital system does not have the capacity to handle the increased load of serious illness presenting to emergency departments. In responding to the grim total, Ms Hammat pointed to the government's efforts to divert people away from hospitals as a success. The minister singled out the Virtual Emergency Department program, which connects patients with doctors before they reach hospital. She said a trial of the program enabled 74 per cent of people who called for an ambulance to receive care without going to an emergency department. That could help explain why the number of semi-urgent and non-urgent cases in WA's emergency departments reduced by about 10 per cent between 2020-21 and 2023-24. But it was not enough to offset a 15 per cent increase in the two most serious categories – resuscitation and emergency – over that same period. 'Where people may have presented with severe diabetes in the past, they're now presenting in renal failure and needing a transplant,' Dr Hoath said. 'People are more unwell because they're not getting the care they need at the right time.' That's a tricky problem to solve but would likely be helped in the long run by increased bulk billing rates – which the federal government could face an uphill battle to do – and more care in the community, rather than in hospitals. But that's also much easier said than done. The opposition was squeezing the terrible report card on WA's health system for every political point it could on Friday. 'Don't build race tracks, don't build movie studios, don't do those other things,' leader Basil Zempilas said. 'My strongest advice for the premier would be: make it your number-one focus. 'That means every day when you get up, and you drive up from Kwinana, don't think about other projects. 'Think about health. Make that your job, your responsibility, until the people of Western Australia know that ambulance ramping is on the way down.' It's an idea many would challenge. Governments can, and do, handle doing many things at the same time, while prioritising some issues over others. But shadow health spokesperson Libby Mettam made a point many would agree with. 'How is it in a state as wealthy as Western Australia that we have such a crumbling health system?' she asked. The answer is there's no simple answer. Building a health system which can meet the growing demands of a rapidly aging population is one of the most wicked problems governments across Australia face. Add in a worse-than-usual flu season with low vaccination rates and there's little surprise hospitals are so full. Earlier last week, having investigated the deaths of three people who passed away while ramped, a South Australian Coroner called on that state's government to acknowledge ramping is 'a reality that all modern healthcare systems encounter'. 'While efforts to reduce the levels of ramping remain extremely important, efforts must also be made to make the process of ramping safer for those patients who will inevitably experience it,' Acting Deputy State Coroner Ian White concluded. That might be an unpalatable answer for many. But if growing demand for healthcare continues to massively outstrip government's ability to meet it, that focus might make the best of a bad situation until the effects of wider reforms start to be felt.
